Panel of experts discussing targeted therapies to deliver improved patient outcomes in oncology.
Exploring opportunities to improve the quality of life for those with Amyotrophic Lateral Sclerosis (ALS)
View our Market Insights webinar to explore the latest practice recommendations in the management and treatment of food allergies.
Wet age-related macular degeneration is a condition that can lead to significant vision loss. It is treated with regular injections, which often work well at preventing vision loss but are a burden to patients with the condition.
View our Market Insights webinar to explore strategies to optimize patient outcomes and manage costs in Wet Age-Related Macular Degeneration
Health care leaders will need plans for handling new treatments for inherited blood disorders. This might mean changing benefits for treatments to make sure patients can get gene therapy.
The expanding use of continuous glucose monitoring (CGM) has been transformative in diabetes care, providing valuable real-time data and insights for diabetes management. CGM coverage in Type 2 diabetes (T2D) has increased, reaching a broader population of patients with diabetes who are recommended for CGM per clinical guidelines.
Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder (lymphoid neoplasm). It is characterized by a progressive accumulation of functionally incompetent B lymphocytes, which are usually monoclonal in origin.
Explore actionable strategies to optimize oncology care with targeted therapies. This document offers health plan best practices, focusing on patient safety, equitable access, and evidence-based policies for effective cancer treatment. Discover innovative tools, multidisciplinary approaches, and transparent policies designed to improve patient and provider outcomes.
Hear from a panel of experts discuss the role of BTKi's in the management of chronic lymphocytic leukemia (CLL)
Diabetes technology is the hardware, devices, and software that people with diabetes use to help manage their condition. Diabetes technology has expanded to include complex devices that both monitor blood sugar and deliver insulin. The American Diabetes Association now recommends use of continuous glucose monitoring (CGM) in individuals with both type 1 and type 2 diabetes. Rapid change in the diabetes technology landscape may lead to access barriers that can impact health plan programs, necessitating appropriate coverage policies.
View our Market Insights webinar to explore the latest practice recommendations in the management and treatment of food allergies.
